메뉴 바로가기 본문 바로가기

TEST ITEMS

THE GENERATION DIAGNOSTIC SYSTEM

Anti-CCP

Rheumatoid Arthritis (RA) is a common, systemic autoimmune disease that 0.5-1.0% of the world population is affected. RA is characterized by chronic inflammation of the synovium which can lead to progressive joint destruction, disability and mortality. As joint damage is irreversible, early therapeutic intervention is of paramount importance for the prognosis of patients.
The most frequent serological diagnostic testing is the measurement of rheumatoid factor (RF). The RF antibody is present in about 75% of RA patients, but its specificity is limited, as it is often present in healthy individuals and patients with other rheumatic or inflammatory diseases, autoimmune diseases or chronic infections.
Recently, new specific autoantibodies to citrullinated proteins antigens (ACPAs) have made a crucial contribution to the diagnosis of RA. Although many assays are available to test for ACPAs to specific antigens, for the clinical management of RA, most ACPA testing is performed using a synthetic cyclic citrullinated protein (CCP) as the antigen to detect ACPAs. An anti-CCP assay is capable to detect the autoantibodies against citrullinated proteins which have a relatively high sensitivity (reportedly between 50-75%) for rheumatoid arthritis and extremely high specificity (about 90%) for RA. Its high specificity is why the anti-CCP test has become an important part of the diagnostic process for RA.

References

  • 1. Birch JT Jr, Bhattacharya S. Emerging trends in diagnosis and treatment of rheumatoid arthritis. Prim Care. 2010;37:779–92.
  • 2. Landewe RB. The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 2003;48(1):1-5.
  • 3. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
  • 4. Mageed RA. The RF antigen. In Manual of Biological Markers of Disease Edited by van Venrooij WJ & Maini RN Dordrecht: Kluwer Academic Publishers; 1996. pp. 1–27.
  • 5. van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res2002;4:87–93
  • 6. Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis.Whiting PF, Smidt N, Sterne JA, Harbord R, Burton A, Burke M, Beynon R, Ben-Shlomo Y, Axford J, Dieppe P Ann Intern Med. 2010 Apr 6; 152(7):456-64; W155-66.
  • 7. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ Arthritis Rheum. 2000 Jan; 43(1):155-63.

ichroma™

Compatible Device ichroma™ I/II
Sample Type Whole Blood,
Serum, Plasma
Sample Volume 5uL(Serum, Serum)
10uL(Whole Blood)
Working Range 5~200 U/mL
Cut-off 5 U/mL
Overall Agreement(Compared with: Elecsys Anti-CCP) 91.3%
Reaction Time 12Min

Product News